Zoom imageAt Bayer in Berkeley (from left): Prof. Dr. Wolfgang Plischke, Bayer employee Monique Mendoza, Chancellor Merkel and Greg Babe.
Prominent visitor to Bayer in Berkeley: German Chancellor Dr. Angela Merkel spent nearly an hour during her recent U.S. visit getting first-hand information from Bayer about the benefits the biotechnology cluster in Berkeley, California, has to offer and the complex biotechnological development and production of the hemophilia treatment Kogenate®.
She was accompanied by a high-ranking political delegation and nearly 40 German journalists. Prof. Dr. Wolfgang Plischke, member of the Bayer AG Board of Management; Greg Babe, Senior Bayer Representative for North America; and Jörg Heidrich, Head of Product Supply Biotechnology, provided an overview of the political, scientific and economic framework in Berkeley.
After a round of discussions, Chancellor Merkel also took a tour of the highly modern packaging lines at the Kogenate® production facility. She and her delegation appeared very impressed with Bayer’s high-tech manufacturing process.